EXACT Therapeutics launches new share option program for insiders

EXACT Therapeutics AS announced today the introduction of a new long-term incentive program for share options, replacing the previous scheme. Under the new program, the company will issue a total of 1,069,643 options. These options will vest in tranches, contingent on participants' continuous employment, and will be exercisable during designated windows following vesting periods. Each option grants the right to purchase one share at a strike price determined by the board, with settlement in either shares or cash.

The transition involves the lapsing of options held by primary insiders under the current incentive program, with new options awarded to these individuals. Specifically, Per Walday received 610,643 options, Amir Snapir received 120,000 options, and John M. Edminson, Caspar Foghsgaard, and Svein Kvåle each received 60,000 options. All options were granted at a price of 0, with a transaction date of November 24, 2025, outside a trading venue.

This new program is designed to provide long-term incentives and is in accordance with EU Market Abuse Regulation and the Norwegian Securities Trading Act. EXACT Therapeutics is a clinical-stage precision medicine company focused on utilizing ultrasound and microbubbles for targeted drug delivery in oncology and brain diseases.